Navigation Links
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
Date:12/7/2007

p> results of cardiac monitoring indicate possible cardiac injury, the

benefit of therapy must be weighed against the risk of myocardial

injury

-- In the randomized multiple myeloma study, 25 patients (8%) in the

VELCADE for Injection arm and 42 patients (13%) in the VELCADE plus

DOXIL arm experienced left ventricular ejection fraction decrease

(defined as absolute decrease greater than or equal to 15% over

baseline or a greater than or equal to 5% decrease below

institutional lower limit of normal)

-- Myelosuppression may occur; frequently monitor complete blood count

(including platelet count), at least prior to each dose of DOXIL

-- In patients with multiple myeloma, hematologic toxicity (based on

platelet count, absolute neutrophil count, hemoglobin level, or

neutropenia with fever) may require dose reduction, delay in

administration, or suspension of DOXIL and/or VELCADE

-- Persistent severe myelosuppression may result in superinfection,

neutropenic fever, or hemorrhage

-- Sepsis occurring during neutropenia has resulted in discontinuation

of treatment and in rare cases of death

-- DOXIL may potentiate the toxicity of other anticancer therapies,

especially hematologic toxicities, when used in combination with other

therapies that suppress bone marrow

-- Hand-foot syndrome (HFS) may occur during therapy with DOXIL

-- Based on HFS toxicity grade, dose reduction, delay in

administration, or discontinuation of DOXIL may be required

-- HFS was generally observed after 2 to 3 cycles of treatment, but may

occur earlier

-- The reaction was mild in most patients, resolving in 1 to 2 weeks

-- The reaction can be severe and debilitating in some patients,

resulting in
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... is available in its catalogue: Germany ... 2020 http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Outlook to 2020 Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- EDGE Orthopaedics, a new entry in ... announce they have received their second FDA 510(k) ... Fracture Plating System. The VIEW Plating ... indications within the mid-foot. The system includes titanium ... (CC), Talonavicular (TN) and Evans plates along with ...
(Date:8/28/2014)... CITY , Aug. 28, 2014 /PRNewswire-iReach/ -- Academy ... by service academy graduates, has published a case ... three-day Leadership Excellence Course . In September and ... Excellence Course to Albuquerque , Indianapolis ... . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
Breaking Medicine Technology:Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9EDGE Orthopaedics Receives Second FDA Clearance 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... Cancer Journal , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007--Introgen,Therapeutics, ... the dramatic clinical benefit of its lead product,Advexin ... of cancer known as,Li-Fraumeni Syndrome (LFS), a genetic ... suppressor gene. This is the,first reported treatment of ...
... CITY, Calif.--(BUSINESS WIRE)--May 29, 2007 - Gilead,Sciences, ... III,AIR-CF1 (CP-AI-007) study of aztreonam lysine for ... fibrosis (CF) who have,pulmonary Pseudomonas aeruginosa (P. ... at Day 28 from baseline in respiratory,symptoms, ...
Cached Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:8/29/2014)... neuroregenerative effect, stimulating neurite extension in the ... and enhancing nerve regeneration following nerve crush ... FK506 to stimulate nerve regeneration is limited ... and hypertension, and its considerable cost. With ... other drugs reportedly cause life-threatening infections. Like ...
(Date:8/29/2014)... August 29, 2014 The Fresh Diet, ... introduce its new Fresh Vegetarian meal plan. Originating from ... meals, the new menu is designed to satisfy customers ... lifestyle. , Responding to the growing demand ... a multi-billion dollar market (Forbes) with 14% of Americans ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Researchers have ... in their brains. Dyslexia -- the most commonly ... problems with reading and writing. Previous research showed ... but most of those studies focused only on a ... used functional MRI to analyze how multiple brain regions ...
(Date:8/29/2014)... VA (PRWEB) August 29, 2014 For ... Research Foundation (Meso Foundation) will be observing September 26th ... on Rockefeller Plaza, in New York. , Members ... encouraged to RSVP . The Foundation will be providing ... the past years, mesothelioma community members have received attention ...
Breaking Medicine News(10 mins):Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Scientists Find Differences in Brains of Those With Dyslexia 2Health News:Organization to Raise Awareness of Mesothelioma on the Today Show 2
... A night of food and festivities for a great ... ActionAIDS has shown their appreciation for people who through ... a very real difference in the lives of men, ... recognizes those individuals with their highest honor: The ...
... structuring physician payment incentives around existing empirical evidence ... reduce the cost of healthcare, says a commentary ... Circulation: Cardiovascular Quality and Outcomes . ... suffering from mild chest pain due to coronary ...
... 20 Young Innovations, Inc. (Nasdaq: YDNT ) today ... a live and on-demand web cast conference call on Tuesday, April ... broadcast of the call will be available through InterCall at ... live audio broadcast will also be available through the Company,s website, ...
... Eli Lilly and Company (NYSE: LLY ) today ... $0.49 a share on outstanding common stock. This is ... and maintains the annual indicated dividend rate for 2009 of ... shareholders of record at the close of business on May ...
... (Nasdaq: AMGN ) today announced that it plans ... 23, 2009 after the close of the financial markets. The ... investment community at 2 p.m. Pacific Time. Participating in ... chief executive officer, and other members of Amgen,s senior management ...
... 8-ounce glass enhances absorption of rapamycin 3 to 4 times ... boosts the anti-cancer effects of the drug rapamycin, according to ... tumors, for which there is no effective treatment. , ... as a liquid, once a week. After the first week ...
Cached Medicine News:Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 2Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 3Health News:Subaru of America CMO Tim Mahoney and Restaurateur Stephen Starr to receive ActionAIDS' Friend for Life Award April 30 4Health News:Health-care reform should start with paying evidence-based financial incentives to doctors 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Amgen Announces Webcast of 2009 First Quarter Financial Results 2Health News:Grapefruit Juice Boosts Anti-Cancer Drug's Effects 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: